Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Research & Development (2016 - 2025)

Historic Research & Development for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $29000.0.

  • Fennec Pharmaceuticals' Research & Development fell 7010.31% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $280000.0, marking a year-over-year decrease of 311.42%. This contributed to the annual value of $307000.0 for FY2024, which is 44821.43% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Research & Development of $29000.0 as of Q3 2025, which was down 7010.31% from $107000.0 recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Research & Development peaked at $2.4 million during Q1 2021, and registered a low of -$927000.0 during Q4 2022.
  • Moreover, its 5-year median value for Research & Development was $95500.0 (2024), whereas its average is $418777.8.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Research & Development plummeted by 9972.16% in 2023, and later soared by 303333.33% in 2025.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Research & Development stood at $1.2 million in 2021, then plummeted by 174.64% to -$927000.0 in 2022, then soared by 103.45% to $32000.0 in 2023, then soared by 56.25% to $50000.0 in 2024, then tumbled by 42.0% to $29000.0 in 2025.
  • Its last three reported values are $29000.0 in Q3 2025, $107000.0 for Q2 2025, and $94000.0 during Q1 2025.